Interim report of toxicity from 3D conformal radiation therapy (3Dd-CRT) for prostate cancer on 3DOG/RTOg 9406, level III (79.2 Gy)
Interim report of toxicity from 3D conformal radiation therapy (3Dd-CRT) for prostate cancer on 3DOG/RTOg 9406, level III (79.2 Gy)
复制标题
DOI：
10.1016/s0360-3016(02)03006-7
复制
发表时间：
2002-11-15
影响因子：
7
通讯作者：
Cox, JD
中科院分区：
文献类型：
--
作者：
Ryu, JK;Winter, K;Cox, JD
目的：进行了一项前瞻性I期剂量递增研究，以确定接受三维适形放疗（3D-CRT）治疗局限性前列腺癌的男性的最大耐受辐射剂量。本文报告了9406三维肿瘤组/放射治疗肿瘤组（RTOG）Ⅲ级剂量（79.2戈伊）下的毒性反应。方法和材料：1996年11月26日至1998年10月1日，173例临床器官局限性前列腺癌（T1和T2）患者接受Ⅲ级剂量79.2戈伊。169例患者可用于毒性分析。根据前列腺特异性抗原（PSA）和Gleason评分，将患者根据精囊浸润（SVI）的风险分为两组。第1组患者具有计算的SVI风险
Purpose: A prospective Phase I dose escalation study was conducted to determine the maximally tolerated radiation dose in men treated with three-dimensional conformal radiotherapy (3D-CRT) for localized prostate cancer. This is a preliminary report of toxicity at Level III (79.2 Gy) on 3D Oncology Group/Radiation Therapy Oncology Group (RTOG) 9406.Methods and Materials: Between November 26, 1996 and October 1, 1998, 173 patients with clinically organ-confined prostate cancer (T1 and T2) were accrued to a Level III dose of 79.2 Gy. One hundred sixty-nine patients were available for analysis of toxicity. Patients were registered to two groups according to the risk of seminal vesicle invasion (SVI) on the basis of presenting PSA and Gleason score. Group 1 patients had a calculated risk of SVI